Literature DB >> 10446970

Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.

S Yamamoto1, A Romanenko, M Wei, C Masuda, W Zaparin, W Vinnichenko, A Vozianov, C C Lee, K Morimura, H Wanibuchi, M Tada, S Fukushima.   

Abstract

After the Chernobyl accident, the incidence of urinary bladder cancers in the Ukraine population increased gradually from 26.2 to 36.1 per 100,000 between 1986 and 1996. Urinary bladder epithelium biopsied from 45 male patients with benign prostatic hyperplasia living in radiocontaminated areas of Ukraine demonstrated frequent severe urothelial dysplasia, carcinoma in situ, and a single invasive transitional cell carcinoma, combined with irradiation cystitis in 42 cases (93%). No neoplastic changes (carcinoma in situ or transitional cell carcinoma) were found in 10 patients from clean areas (areas without radiocontamination). DNA was extracted from the altered urothelium of selected paraffin-embedded specimens that showed obviously abnormal histology (3 cases) or intense p53 immunoreactivity (15 cases), and mutational analysis of exons 5-8 of the p53 gene was performed by PCR-single-strand conformational polymorphism analysis followed by DNA sequencing. Nine of 17 patients (53%) had one or more mutations in the altered urothelium. Urine sediment samples were also collected from the patients at 4-27 months after biopsy and analyzed by PCR-single-strand conformational polymorphism analysis or yeast functional assay, and identical or additional p53 mutations were found in four of five cases. Interestingly, a relative hot spot at codon 245 was found in five of nine (56%) cases with mutations, and 11 of the 13 mutations determined (73%) were G:C to A:T transitions at CpG dinucleotides, reported to be relatively infrequent (approximately 18%) in human urinary bladder cancers. Therefore, the frequent and specific p53 mutations found in these male patients may alert us to a future elevated occurrence of urinary bladder cancers in the radiocontaminated areas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446970

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.

Authors:  David S Yee; Shahrokh F Shariat; William T Lowrance; Joseph R Sterbis; Kinjal C Vora; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni; Jaspreet S Sandhu
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

2.  Secondary malignancies following radiotherapy for prostate cancer.

Authors:  Petros Sountoulides; Nikolaos Koletsas; Dimitris Kikidakis; Konstantinos Paschalidis; Nikolaos Sofikitis
Journal:  Ther Adv Urol       Date:  2010-06

3.  Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.

Authors:  Joshua I Warrick; Daniel H Hovelson; Anmol Amin; Chia-Jen Liu; Andi K Cani; Andrew S McDaniel; Venkata Yadati; Michael J Quist; Alon Z Weizer; J Chad Brenner; Felix Y Feng; Rohit Mehra; Catherine S Grasso; Scott A Tomlins
Journal:  Virchows Arch       Date:  2014-12-11       Impact factor: 4.064

4.  Environmental exposure, chlorinated drinking water, and bladder cancer.

Authors:  Peter J Goebell; Cristina M Villanueva; Albert W Rettenmeier; Herbert Rübben; Manolis Kogevinas
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

5.  Secondary malignancy after radiotherapy: not always a secondary concern.

Authors:  Vishruth K Reddy; Neha Vapiwala
Journal:  Nat Rev Urol       Date:  2021-09       Impact factor: 14.432

6.  Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Kenjiro Imada; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Saiji Ohga; Katsumasa Nakamura; Hiroshi Honda; Seiji Naito
Journal:  Oncotarget       Date:  2015-06-10

7.  p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry.

Authors:  S Yamamoto; M Tada; C C Lee; C Masuda; H Wanibuchi; R Yoshimura; S Wada; K Yamamoto; T Kishimoto; S Fukushima
Journal:  Jpn J Cancer Res       Date:  2000-02

8.  Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.

Authors:  Thekra A Al-Kashwan; Massoud Houshmand; Asaad Al-Janabi; Alice K Melconian; Dhafir Al-Abbasi; Muhammad N Al-Musawi; Maryam Rostami; Akeel A Yasseen
Journal:  BMC Res Notes       Date:  2012-08-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.